Complete List of Published Work in My Bibliography

https://www.ncbi.nlm.nih.gov/myncbi/16Q7sxcnhxBA-/bibliography/public/    

​​​

Publications from 2018-present:

​

Peer-Reviewed Articles

​

1.            Li X, Liu R, Huang Z, Gurley EC, Wang X, Wang J, He H, Yang H, Lai G, Zhang L, Bajaj JS, White M, Pandak WM, Hylemon PB, ZHOU H. Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and humans. Hepatology. 2018;68:599–615.

​

2.            Liu R, Li X, Huang Z, Zhao D, Ganesh BS, Lai G, Pandak WM, Hylemon PB, Bajaj JS, Sanyal AJ, ZHOU H. C/EBP homologous protein-induced loss of intestinal epithelial stemness contributes to bile duct ligation-induced cholestatic liver injury in mice. Hepatology. 2018;67:1441–1457.

​

3.            Liu R, Li X, Hylemon PB, ZHOU H. Conjugated bile acids promote invasive growth of esophageal adenocarcinoma cells and cancer stem cell expansion via sphingosine-1-phosphate receptor 2-mediated Yes-associated protein activation. Am J Pathol. 2018;188:2042–2058.

​

4.            Wan XS, Wang X, Xiao J, Li XK, ZHOU H. Corrigendum to “ATF4- and CHOP-Dependent Induction of FGF21 through Endoplasmic Reticulum Stress.” Biomed Res Int. 2018;3218606.

​

5.            Zhou D, Chen YW, Zhao ZH, Yang RX, Xin FZ, Liu XL, Pan Q, ZHOU H, Fan JG. Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression. Exp Mol Med. 2018;50:157.

​

6.            Chen X, Chen X, Zhang X, Wang L, Cao P, Rajamanickam V, Wu C, ZHOU H, Cai Y, Liang G, Wang Y. Curcuminoid B63 induces ROS-mediated paraptosis-like cell death by targeting TrxR1 in gastric cells. Redox Biol. 2019;21:101061.

​

7.            Chen YY, Tang YP, Shang EX, Zhu ZH, Tao WW, Yu JG, Feng LM, Yang J, Wang J, Su SL, ZHOU H, Duan JA. Incompatibility assessment of Genkwa Flos and Glycyrrhizae Radix et Rhizoma with biochemical, histopathological and metabonomic approach. J Ethnopharmacol. 2019;229:222–232.

​

8.            Kakiyama G, Marques D, Takei H, Nittono H, Erickson S, Fuchs M, Rodriguez-Agudo D, Gil G, Hylemon PB, ZHOU H, Bajaj JS, Pandak WM. Mitochondrial oxysterol biosynthetic pathway gives evidence for CYP7B1 as controller of regulatory oxysterols. J Steroid Biochem Mol Biol. 2019;189:36–47.

​

9.            Kang JD, Myers CJ, Harris SC, Kakiyama G, Lee IK, Yun BS, Matsuzaki K, Furukawa M, Min HK, Bajaj JS, ZHOU H, Hylemon PB. Bile acid 7α-dehydroxylating gut bacteria secrete antibiotics that inhibit Clostridium difficile: Role of secondary bile acids. Cell Chem Biol. 2019;26:27–34.

​

10.          Liu R, Ahluwalia V, Kang JD, Ghosh SS, ZHOU H, Li Y, Zhao D, Gurley E, Li X, White MB, Fagan A, Lippman HR, Wade JB, Hylemon PB, Bajaj JS. Effect of increasing age on brain dysfunction in cirrhosis. Hepatol Commun. 2019;3:63–73.

​

11.          Yi H, Xu D, Wu X, Xu F, Lin L, ZHOU H. Isosteviol protects free fatty acid- and high-fat diet-induced hepatic injury via PKC-β/p66Shc/ROS and ER stress pathways. Antioxid Redox Signal. 2019;30:1949–1968.

​

12.          Kwong EK, Liu R, Zhao D, Li X, Zhu W, Wang X, Gurley EC, Lai G, Liu J, Hylemon PB, ZHOU H. The role of sphingosine kinase 2 in alcoholic liver disease. Dig Liver Dis. 2019;51:1154–1163.

​

13.          Liu R, Li X, Zhu W, Wang Y, Zhao D, Wang X, Gurley EC, Liang G, Chen W, Lai G, Pandak WM, Lippman HR, Bajaj JS, Hylemon PB, ZHOU H. Cholangiocyte-derived exosomal long noncoding RNA H19 promotes hepatic stellate cell activation and cholestatic liver fibrosis. Hepatology. 2019;70:1317–1335.

​

14.          Xiao Y, Liu R, Li X, Gurley EC, Hylemon PB, Lu Y, ZHOU H, Cai W. Long noncoding RNA H19 contributes to cholangiocyte proliferation and cholestatic liver fibrosis in biliary atresia. Hepatology. 2019;70:1658–1673.

​

15.          Liu R, Kang JD, Sartor RB, Sikaroodi M, Fagan A, Gavis EA, ZHOU H, Hylemon PB, Herzog JW, Li X, Lippman RH, Maeso JG, Wade JB, Ghosh S, Gurley E, Gillevet PM, Bajaj JS. Neuroinflammation in murine cirrhosis is dependent on the gut microbiome and attenuated by fecal transplant. Hepatology. 2020;71:611–626.

​

16.          Bajaj JS, Sharma A, Dudeja PK. Targeting gut microbiome interactions in service-related gastrointestinal and liver diseases of Veterans. Gastroenterology. 2019;157:1180–1183.

​

17.          Liu XL, Pan Q, Cao HX, Xin FZ, Zhao ZH, Yang RX, Zeng J, ZHOU H, Fan JG. Lipotoxic hepatocyte-derived exosomal miR-192-5p activates macrophages via Rictor/Akt/FoxO1 signaling in NAFLD. Hepatology. 2020;72:454–469.

​

18.          Ma Y, Wang W, Devarakonda T, ZHOU H, Wang XY, Salloum FN, Spiegel S, Fang X. Functional analysis of molecular and pharmacological modulators of mitochondrial fatty acid oxidation. Sci Rep. 2020;10:1450.

​

19.          Li X, Liu R, Wang Y, Zhu W, Zhao D, Wang X, Yang H, Gurley EC, Chen W, Hylemon PB, ZHOU H. Cholangiocyte-derived exosomal lncRNA H19 promotes macrophage activation and hepatic inflammation under cholestatic conditions. Cells. 2020;9:190.

​

20.          Wang X, Zhou X, Zhao D, Wang X, Gurley EC, Liu R, Li X, Hylemon PB, Chen W, ZHOU H. Berberine inhibits free fatty acid- and LPS-induced inflammation via modulating ER stress in macrophages and hepatocytes. PLoS One. 2020;15:e0232630.

​

21.          Mazzini GS, Khoraki J, Browning MG, Wu J, ZHOU H, Price ET, Wolfe LG, Mangino MJ, Campos GM. Gastric bypass increases circulating bile acids and activates hepatic FXR but requires intact PPARα signaling to reduce liver fat. J Gastrointest Surg. 2021;25:871–879.

​

22.          Kakiyama G, Marques D, Martin R, Takei H, Rodriguez-Agudo D, LaSalle SA, Hashiguchi T, Liu X, Green R, Erickson S, Gil G, Fuchs M, Suzuki M, Murai T, Nittono H, Hylemon PB, ZHOU H, Pandak WM. Insulin resistance dysregulates CYP7B1 leading to oxysterol accumulation: a pathway for NAFL to NASH transition. J Lipid Res. 2020;61:1629–1644.

​

23.          Wang Y, Tai Y, Zhao D, Zhang Y, Yan J, Kakiyama G, Wang X, Gurley EC, Liu J, Lai G, Hylemon PB, Pandak WM, Che W, ZHOU H. Berberine prevents disease progression of nonalcoholic steatohepatitis through modulating multiple pathways. Cells. 2021;10:210.

​

24.          Zhang Y, Kang JD, Zhao D, Ghosh SS, Wang Y, Tai Y, Gonzalez-Maeso J, Sikaroodi M, Gillevet PM, Lippman RH, Hylemon PB, ZHOU H, Bajaj JS. Hepatic branch vagotomy modulates the gut–liver–brain axis in murine cirrhosis. Front Physiol. 2021;12:702646.

​

25.          Tian X, Wang Y, Lu Y, Wang W, Du J, Chen S, ZHOU H, Cai W, Xiao Y. Conditional depletion of macrophages ameliorates cholestatic liver injury and fibrosis via lncRNA-H19. Cell Death Dis. 2021;12:646.

​

26.          Ding Y, Zhang S, Sun Z, Tong Z, Ge Y, Zhou L, Xu Q, ZHOU H, Wang W. Preclinical validation of silibinin/albumin nanoparticles as an applicable system against acute liver injury. Acta Biomater. 2022;146:385–395.

​

27.          Wang Y, Tai YL, Way G, Zeng J, Zhao D, Su L, Jiang X, Jackson KG, Wang X, Gurley EC, Liu J, Chen W, Wang XY, Sanyal AJ, Hylemon PB, ZHOU H. RNA-binding protein HuR protects against NAFLD by suppressing long noncoding RNA H19 expression. Cell Biosci. 2022;12:172.

​

28.          Kakiyama G, Minowa K, Rodriguez-Agudo D, Martin R, Takei H, Mitamura K, Ikegawa S, Mitsuyoshi S, Nittono H, Fuchs M, Heuman DM, ZHOU H, Pandak WM. Coffee modulates insulin–HNF-4α–Cyp7b1 pathway and reduces oxysterol-driven liver toxicity in a NAFLD mouse model. Am J Physiol Gastrointest Liver Physiol. 2022;323:G488–G500.

​

29.          Wolstenholme JT, Saunders JM, Smith M, Kang JD, Hylemon PB, González-Maeso J, Fagan A, Zhao D, Sikaroodi M, Herzog J, Shamsaddini A, Peña-Rodríguez M, Su L, Tai YL, Zheng J, Cheng PC, Sartor RB, Gillevet PM, ZHOU H, Bajaj JS. Reduced alcohol preference after fecal transplant in alcohol use disorder patients is transmissible to germ-free mice. Nat Commun. 2022;13:6198.

​

30.          Awoniyi M, Wang J, Ngo B, Meadows V, Tam J, Viswanathan A, Lai Y, Montgomery S, Farmer M, Kummen M, Thingholm L, Schramm C, Bang C, Franke A, Lu K, ZHOU H, Bajaj JS, Hylemon PB, Ting J, Popov YV, Hov JR, Francis HL, Sartor RB. Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in PSC. Gut. 2023;72:671–685.

​

31.          Wang W, Hawkridge AM, Ma Y, Zhang B, Mangrum JB, Hassan ZH, He T, Blat S, Guo C, ZHOU H, Liu J, Wang XY, Fang X. Ubiquitin-like protein 5 is a novel player in the UPR-PERK arm and ER stress-induced cell death. J Biol Chem. 2023;299:104915.

​

32.          Sarkar J, Aoki H, Wu R, Aoki M, Hylemon P, ZHOU H, Takabe K. Conjugated bile acids accelerate progression of pancreatic cancer metastasis via S1PR2 signaling in cholestasis. Ann Surg Oncol. 2023;30:1630–1641.

​

33.          Guo C, Liu W, Liu Z, Cai J, Yu X, Wang H, Li X, Zuo D, Jiang X, Zhang B, Liu J, Sanyal AJ, Puri P, ZHOU H, Wang XY. Scavenger receptor A restrains drug-induced liver injury as a homeostatic regulator. Hepatology. 2023;78:45–57.

​

34.          Way G, Lu H, Wang X, Zhao D, Camarena C, Sarkar D, Martin RK, ZHOU H. Optimization of high-throughput spectral flow cytometry for immune cell profiling in mouse liver. Liver Res. 2023;7:263–271.

​

35.          Wu H, Guo C, Liu Z, Cai J, Wang C, Yi H, Sanyal A, Puri P, ZHOU H, Wang XY. Neutrophils exacerbate acetaminophen-induced liver injury by producing cytotoxic interferon-γ. Int Immunopharmacol. 2023;123:110734.

​

36.          Wang Y, Zhao D, Su L, Tai YL, Way GW, Zeng J, Yan Q, Xu Y, Wang X, Gurley EC, Zhou XQ, Liu J, Chen W, Hylemon PB, ZHOU H. Therapeutic potential of berberine in attenuating cholestatic liver injury: insights from a PSC mouse model. Cell Biosci. 2024;14:14.

​

37.          Bajaj JS, Fagan A, Gavis EA, Mousel T, Gallagher ML, Puri P, Fuchs M, Davis BC, Hylemon PB, ZHOU H, Ahluwalia V, Cadrain R, Sikaroodi M, Gillevet PM. The RIVET RCT: Rifamycin SV MMX improves muscle mass and cognition in cirrhosis. Hepatol Commun. 2024;8:e0384.

​

38.          Jiang X, Xu Y, Fagan A, Patel B, ZHOU H, Bajaj JS. Single-nuclear RNA sequencing of terminal ileum in cirrhosis reveals multifaceted intestinal barrier alterations. Cell Biosci. 2024;14:25.

​

39.          Fu X, Mackowiak B, Lin Y, Lehner T, Pan H, Guan Y, Godlewski G, Lu H, Chen C, Maccioni L, Feng D, Paloczi J, ZHOU H, Pacher P, Zhang L, Kunos G, Gao B. Coordinated action of a gut–liver pathway drives alcohol detoxication and consumption. Nat Metab. 2024;6:1380–1396.

​

40.          Jackson KG, Zhao D, Su L, Lipp MK, Toler C, Idowu M, Saeed A, Yan Q, Wang X, Gurley EC, Wu N, Puri P, Chen Q, Lesnefsky EJ, Dupree JL, Hylemon PB, ZHOU H. Sphingosine kinase 2 depletion dysregulates hepatic redox metabolism and enhances inflammation in diet-induced MASH. Hepatol Commun. 2024;8:e0570.

​

41.          Zeng J, Zhao D, Way GW, Fagan A, Fuchs M, Puri P, Davis B, Wang X, Gurley EC, Hylemon PB, Fan JG, Sikaroodi M, Gillevet P, ZHOU H, Bajaj JS. Intestinal mitochondrial oxidative phosphorylation worsens with cirrhosis progression and improves with FMT. JCI Insight. 2025;e186649.

​

42.          Oshins R, Huo Z, Poole B, Clark V, ZHOU H, West J, Wheeler M, Aghaee M, He M, Brantly M, Khodayari N. Plasma extracellular vesicle-derived microRNA associated with A1AT deficiency-mediated liver disease. J Clin Transl Hepatol. 2025;13:118–129.

​

43.          Nie L, Cheng Z, He Y, Yan Q, Sun Y, Yang X, Tian J, Zhu P, Yu J, ZHOU H, Zhou X. Role of duodenal mucosal resurfacing in controlling diabetes in rats. World J Diabetes. 2025;16:102277.

​

44.          Zeng J, Way G, Wu N, Jiang X, Tai YL, Zhao D, Su L, Yan Q, Wang X, Gurley EC, Hylemon PB, Aseem SO, Sanyal AJ, Fan JG, ZHOU H. Transcriptomics, lipidomics, and single-nucleus RNA sequencing integration: sphingolipids in MASH-HCC progression. Cell Biosci. 2025;15:34.

​

45.          Liu Y, Hassan H, Brooks TR, VanLith C, Cooley M, Elgozair M, Ahmed FY, Giama NH, Campbell NA, Su L, Tai Y, ZHOU H, Roberts LR. Interactions between bile acids and short-chain fatty acids in cholangiocarcinoma. J Hepatol Rep. 2025; in press.

​

46.          Liu Y, Zhu J, Jin Y, Sun Z, Wu X, ZHOU H, Yang Y. Disrupting bile acid metabolism by suppressing FXR causes hepatocellular carcinoma via YAP activation. Nat Commun. 2025;16:3583.

​

47.          Aseem SO, Wang J, Kalaiger MF, Way G, Zhao D, Tai YL, Gurley EC, Zeng J, Wang X, Cowart LA, Huebert RC, Hylemon PB, Alan-Sakrikar N, Sanyal AJ, ZHOU H. Aramchol attenuates fibrosis in biliary fibrosis models by blocking TGFβ-induced fibroinflammatory mediators in cholangiocytes. Hepatol Commun. 2025;9:e0748.

​

Review Articles

​

1.            Zhu J, Yi H, Wei H, Tao P, ZHOU H, Wu X. Fatty liver diseases: mechanisms and potential therapeutic plant medicines. Chin J Nat Med. 2020;18:161–168.

​

2.            Wang Y, Hylemon PB, ZHOU H. Long noncoding RNA H19: a key player in liver diseases. Hepatology. 2021;74:1652–1659.

​

3.            Hylemon PB, Su L, Zheng P, Bajaj BS, ZHOU H. Bile acids, gut microbiome, and the road to fatty liver disease. Compr Physiol. 2021;12:2719–2730.

​

4.            Xue R, Su L, Lai S, Wang Y, Zhao D, Fan J, Chen W, Hylemon PB, ZHOU H. Bile acid receptors and the gut–liver axis in NAFLD. Cells. 2021;10:2806.

​

5.            Jackson K, Way G, ZHOU H. Bile acids and sphingolipids in NAFLD. Chin Med J (Engl). 2022;135:1163–1171.

​

6.            Way G, Jackson KG, Muscu SR, ZHOU H. Key signaling in alcohol-associated liver disease: the role of bile acids. Cells. 2022;11:1374.

​

7.            Fasullo M, Shah T, ZHOU H, Siddiqui MS. Post-transplant biliary strictures: an updated review. Semin Liver Dis. 2022;42:225–232.

​

8.            Jackson KG, Way GW, Zeng J, Lipp MK, ZHOU H. The dynamic role of ER stress in chronic liver disease. Am J Pathol. 2023;193:859–872.

​

9.            Zeng J, Fan J, ZHOU H. Bile acid-mediated signaling in cholestatic liver diseases. Cell Biosci. 2023;13:77.

​

10.          Wang Y, Zeng J, Chen W, Fan J, Hylemon PB, ZHOU H. Long noncoding RNA H19: a novel oncogene in liver cancer. Noncoding RNA. 2023;9:19.

​

11.          Aseem SO, Hylemon PB, ZHOU H. Bile acids and biliary fibrosis. Cells. 2023;12:792.

​

12.          Liu R, Li Y, Zheng Q, Ding M, ZHOU H, Li X. Epigenetic modification in liver fibrosis: therapeutic directions and challenges. Acta Pharm Sin B. 2024;14:1009–1029.

​

13.          Wang Y, Xu H, Zhou X, Chen W, ZHOU H. Dysregulated bile acid homeostasis: unveiling its role in metabolic diseases. Med Rev. 2024;4:262–283.

​

14.          Wu N, Bayatpour S, Aseem SO, Brindley PJ, Hylemon PB, ZHOU H. Gut microbiome and bile acid interactions in cholangiocarcinoma development and therapy. Am J Pathol. 2024;194:445–460.

​

15.          Li H, Song M, Hylemon PB, ZHOU H. LECT2–PHB2 axis: a new mechanistic insight and therapeutic opportunity in alcohol-associated hepatitis. Gut. 2025; in press.

​

​​​​​